Qli5 Therapeutics
Dortmund
About Qli5 Therapeutics
Qli5 Therapeutics develops a new class of proteasome inhibitors with high selectivity and unique, non-covalent binding properties.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $15.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: qli5tx.com
Industries & Categories
Medical, Therapeutics
Canonical: https://fsome.com/organization/qli5-therapeutics-54024 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.